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The clinical significance of cytomegalovirus (CMV) DNA detection in post-kidney
transplantation infection surveillance was examined by comparing the performance of
three assays for detection of CMV in blood: the test for CMV-pp65-antigen in leukocytes,
which is routinely employed in our laboratory, the quantitative plasma CMV-DNA-
polymerase chain reaction (PCR; Cobas Amplicor CMV Monitor test1) and the quali-
tative plasma CMV-DNA-PCR (Amplicor CMV test1). Thirteen kidney transplant
recipients were monitored with serial samples taken over a period of 3 months following
transplantation. The quantitative CMV-PCR was the test with highest sensitivity, 95.9%,
vs. 88.9% and 76.9% for the CMV-pp65 antigen assay and qualitative CMV-PCR,
respectively. The virus load in the first positive specimens, assessed as DNA-copies/
mL, was significantly associated with CMV disease because five of the six patients who
developed disease, but only one of the seven who did not develop disease, had more than
3000 CMV-DNA-copies/mL. The number of CMV-pp65 antigen-positive cells in the first
positive specimens did not have predictive value for development of CMV disease.
Assessment of CMV in plasma by the quantitative CMV-PCR is especially useful since it
has a high sensitivity and the amount of CMV DNA in plasma is a good predictor of CMV
disease.
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Cytomegalovirus (CMV) is still a major pathogen
in organ transplant recipients despite the imple-
mentation of new diagnostic tools and improved
strategies for anti-CMV prophylaxis and treat-
ment. In a recent study on CMV infections in
477 kidney transplant recipients, we showed
that among patients at risk for primary CMV
infection, 68% acquired CMV infection, and of
these, 81% developed CMV disease [1]. In patients
at risk for CMV-reactivated infection, 69% had a
reactivated CMV infection but only 26% devel-
oped CMV disease. This illustrates one of the
major problems in the management of CMV
infections in transplant recipients. Only a certain
proportion of patients at risk will have an active
CMV infection and even fewer will develop CMV
disease.
Surveillance of CMV infections in transplant
recipients is usually based on early detection of
CMV in blood. This is based on the fact that
generalized CMV endothelitis is a common feature
of CMV infections in immunosuppressed patients
and that CMV is either released into plasma or is
picked up directly from infected endothelial cells
by the granulocytes [2]. The CMV load in blood is
assessed by applying quantitative methods and
may be useful in the surveillance of CMV infec-
tions [3].
Recently, standardized, semiautomated CMV
polymerase chain reaction (PCR) tests have been
developed which have proved useful in monitor-
ing CMV infection in a variety of organ transplan-
tation settings [4,5].
The present study was undertaken in order to
compare our routine test for quantitative assess-
ment of CMV-pp65-antigen (Ag) in leukocytes
with a quantitative CMV-DNA-PCR (Cobas
Amplicor CMV Monitor1; Roche Diagnostics,
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Basle, Switzerland) and a qualitative CMV-DNA-
PCR (Amplicor CMV1; Roche Diagnostics) for
assessment of CMV DNA in plasma. We intended
to evaluate the clinical utility of these assays in the
surveillance of CMV infections in a cohort of
kidney transplant recipients.
In our hospital, kidney transplant recipients are
tested weekly for CMV-pp65-Ag in leukocytes
during the first 3 months after transplantation. In
the period from September 1998 to the end of
March 1999 a parallel sample of ethylenediamine-
tetraacetic acid-plasma for CMV-PCR was
obtained at the same time-points and immediately
frozen and stored at 70 8C. The CMV-pp65-Ag
test was positive at least once in 39 consecutive
first kidney transplant recipients. None of these
patients received ganciclovir prophylaxis or pre-
emptive therapy.
A quantitative and qualitative CMV-PCR was
performed on 120 plasma samples from 13 of the
39 patients who had CMV disease (n¼ 6) or
asymptomatic CMV infection (n¼ 7) and were
positive for CMV-pp65-Ag in at least three con-
secutive specimens. CMV-PCR was performed on
plasma samples taken at the same time as the
CMV-pp65-Ag positive samples. In addition, at
least one sample that was taken before the first
and after the last CMV-pp65-Ag-positive sample
was examined. The median number of samples per
patient was eight (range 5–18). The patients had
given their informed consent to participate in the
study and the Regional Ethics Committee had
approved the study.
CMV disease was defined as the detection of
CMV in a blood specimen accompanied either by
CMV syndrome with fever, muscle pain or leuko-
penia and/or thrombocytopenia (other causes
excluded) or by organ involvement [1].
The assay for CMV-pp65-Ag in leuco-
cytes was performed as a modification of a
reported procedure [4]. The results were given
as number of CMV-pp65-Ag-positive cells per
105 leukocytes.
The Amplicor CMV1 and Cobas Amplicor
CMV Monitor1 tests are based on the amplifica-
tion of the virus DNA-polymerase gene using
biotinylated primers flanking a 365-base pair con-
served sequence. Amplicons are then captured by
specific hybridization on microwell plates (Ampli-
cor CMV1) or magnetic beads (Cobas Amplicor
CMV Monitor1) and detected by colorimetric
reaction [5,6]. A 200-mL aliquot of plasma is pro-
cessed to isolate CMV DNA after lysis of circulat-
ing viral particles.
In the qualitative Amplicor CMV1 test, the
presence or absence of CMV DNA is established
by comparing the sample O.D. with the negative
cut-off value, while in the quantitative Cobas
Amplicor CMV Monitor1 test, the amount of
CMV DNA is automatically calculated and
expressed in copies/mL over a 103106 copies/
mL dynamic range. A quantification standard,
consisting of a synthetic DNA identical to the
target except for a specific probe-binding
sequence, is added in known amounts to the
sample prior to DNA extraction.
Cobas Amplicor CMV Monitor1 and Amplicor
CMV1 have analytical and clinical sensitivities of
five copies/PCR reaction and 20 viral particles/
PCR reaction, respectively. Both assays make use
of Amperase1 (Uracyl-N-glycosyilase) (Roche
Diagnostics) to prevent carry-over contamination
and use an internal control to ensure result integ-
rity.
Non-parametric methods were generally used
for statistical analysis. Distribution of variables
within groups is generally presented as median
values and ranges. The Mann–Whitney U-test cal-
culated quantitative differences of specific vari-
ables between groups. Quantitative differences
for time-dependent changes of the same variable
were tested by the Wilcoxon matched pairs test.
Kendall’s t (tau) was used as correlation coeffi-
cient. Two-by-two frequency tables were tested
either by using w2 or w2 with Yates correction for
lower observation numbers. All tests were consid-
ered two-tailed.
In immunocompromised patients clinical diag-
nosis of CMV disease is difficult and has to be
supported by detection of CMV in specimens from
the organs affected or, alternatively, by detection
of CMV in blood specimens. Usually CMV can be
detected in blood days or weeks before the onset of
symptoms [1]. By monitoring serial blood samples
for the presence of CMV, emerging infections may
be treated before disease development, i.e. pre-
emptive therapy, or at the early onset of disease,
i.e. deferred therapy.
The sensitivity of the tests was compared in
several ways. When CMV positivity was defined
as a time-point where at least one of the tests were
positive (99/120), 95 (95,9%) were positive with
the quantitative CMV-PCR, 88 (88.9%) were posi-
tive with the CMV-pp65-Ag assay and 76 (76.8%)
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were positive with the qualitative CMV-PCR. Both
the quantitative CMV-PCR and the CMV-pp65-Ag
assay were more sensitive than the qualitative
CMV-PCR (P< 0.05). The quantitative CMV-PCR
tended to be more sensitive than the CMV-pp65-
Ag assay; however, the difference was not statis-
tically significant (0.05<P< 0.1).
In this study the quantitative CMV-PCR
detected 6.25 copies per PCR reaction (250
DNA-copies/mL) which is very close to the
detection limit of five copies per PCR reaction
given by the manufacturer. The CMV-pp65-Ag
assay was positive for all blood samples contain-
ing more than 3480 CMV DNA-copies/mL,
whereas among 43 samples harboring 249–2429
CMV DNA-copies/mL plasma, 33 (76,7%) blood
samples were positive for CMV-pp65-Ag. Four
specimens with CMV-pp65-Ag values ranging
from 1 to 22 positive cells/105 leukocytes, were
negative with the quantitative CMV-PCR. On the
other hand, among 32 CMV-pp65-Ag-negative
samples, 12 samples were positive with the quan-
titative CMV-PCR. However, there was a high
degree of correlation between the quantitative
tests for CMV-pp65-Ag and CMV-DNA when
parallel specimens were tested and CMV was
detected in at least one of the tests [t¼ 0.55,
P< 0.001 (n¼ 99)]. The good correlation between
the quantitative CMV-PCR and the CMV-antige-
nemia test is in agreement with the findings of
Caliendo et al. [7].
To get an early indication of CMV disease, the
assays for detection of CMV in blood have to be
positive, before, or at least when the symptoms
appear. In our patient population the first positive
CMV test appeared approximately 45 (24–54) days
after transplantation for primary CMV infection
and approximately 30 (13–44) days for reactivated
infection (Table 1). However, there was a statisti-
cally significant difference only for the qualitative
CMV-PCR (P< 0.05). Among the six patients with
CMV disease, CMV was found in blood by all
three methods before or at the time of disease
manifestation. There was no statistically signifi-
cant difference between the tests with regard to
time to appearance of first positive test after trans-
plantation. This was true both for primary infec-
tion, reactivated infection, asymptomatic infection
and symptomatic infection (Table 1).
We further tested whether the viral load of the
first positive specimen or the maximum viral load
was predictive of later development of sympto- T
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matic infection. As shown in Table 1, the load of
CMV DNA in plasma in the first positive specimen
of consecutive post-transplant specimens was con-
siderably higher in patients who developed CMV
disease (P¼ 0.022), whereas this was not the case
for the first positive CMV-pp65-Ag test. Five out of
six patients who developed CMV disease but only
one out of seven who did not develop CMV dis-
ease, had more than 3000 CMV DNA-copies/mL
in the first positive specimen.
Maximum viral load and the time of its appear-
ance after transplantation is often used to charac-
terize a CMV infection [8]. In our study, however,
no differences were seen in maximal virus loads
between those developing CMV disease and those
who were asymptomatic when employing any of
the two quantitative CMV tests (results not
shown). In this and previous studies we have
found that the systemic virus load shows a high
variability also among patients who develop CMV
disease so that no virus load can be used as a cut-
off to predict the development of CMV disease.
Several factors other than virus load are of impor-
tance for the development of CMV disease. Nor-
døy et al. showed that the cytokine profile after
transplantation is highly predictive of CMV dis-
ease [9]. High levels of interleukin-8 and low levels
of macrophage inflammatory protein 1 were
recorded among those who developed disease,
even before the onset of CMV infection. A more
reliable prediction of CMV disease may thus be
achieved by combining tests for viral load and for a
relevant cytokine.
In conclusion, both the quantitative (Cobas
Amplicor CMV Monitor test1) and the qualitative
(Amplicor CMV test 1) CMV-DNA-PCR, as well
as the quantitative CMV-pp65-Ag assay have the
sensitivity required to detect CMV in blood before
the onset of CMV disease in kidney transplant
recipients. A high level of CMV DNA in plasma,
but not the number of CMV-pp65-positive leuko-
cytes, in the first positive specimen of sequential
specimens, was highly predictive of later devel-
opment of CMV disease.
R E F E R E N C E S
1. Sagedal S, Nordal KP, Hartmann A et al. A
prospective study of the natural course of cytome-
galovirus infection and disease in renal allograft
recipients. Transplantation 2000; 70: 1166–74.
2. Revello MG, Percivalle E, Arbustini E, Pardi R,
Sozzani S, Gerna G. In vitro generation of human
cytomegalovirus pp. 65 antigenemia, viremia, and
leukoDNAemia. J Clin Invest 1998; 101: 2686–92.
3. Roberts TC, Brennan DC, Buller RS et al. Quantitative
polymerase chain reaction to predict occurrence of
symptomatic cytomegalovirus infection and assess
response to ganciclovir therapy in renal transplant
recipients. J Infect Dis 1998; 178: 626–35.
4. Rollag H, Sagedal S, Holter E, Degre M, Ariansen S,
Nordal KP. Diagnosis of cytomegalovirus infection
in kidney transplant recipients by a quantitative
RNA-DNA hybrid capture assay for cytomegalo-
virus DNA in leukocytes. Eur J Clin Microbiol Infect
Dis 1998; 17: 124–7.
5. Long CM, Drew L, Miner R, Jekic-McMullen D,
Impraim C, Kao SY. Detection of cytomegalovirus in
plasma and cerebrospinal fluid specimens from
human immunodeficiency virus-infected patients
by the AMPLICOR CMV test. J Clin Microbiol 1998;
36: 2434–8.
6. Tong CY, Cuevas LE, Williams H, Bakran A.
Comparison of two commercial methods for mea-
surement of cytomegalovirus load in blood samples
after renal transplantation. J Clin Microbiol 2000; 38:
1209–13.
7. Caliendo AM, St George K, Kao SY et al. Comparison
of quantitative cytomegalovirus (CMV) PCR in
plasma and CMV antigenemia assay: clinical utility
of the prototype AMPLICOR CMV MONITOR test
in transplant recipients. J Clin Microbiol 2000; 38:
2122–7.
8. Hassan-Walker AF, Kidd IM, Sabin C, Sweny P,
Griffiths PD, Emery VC. Quantity of human cyto-
megalovirus (CMV) DNAemia as a risk factor for
CMV disease in renal allograft recipients: relation-
ship with donor/recipient CMV serostatus, receipt
of augmented methylprednisolone and antithymo-
cyte globulin (ATG). J Med Virol 1999; 58: 182–7.
9. Nordøy I, Muller F, Nordal KP et al. Immunologic
parameters as predictive factors of cytomegalovirus
disease in renal allograft recipients. J Infect Dis 1999;
180: 195–8.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 431–434
434 Clinical Microbiology and Infection, Volume 8 Number 7, July 2002
